Email updates

Keep up to date with the latest news and content from BMC Ophthalmology and BioMed Central.

Open Access Highly Accessed Research article

Retrospective analysis of the success and safety of Gold Micro Shunt Implantation in glaucoma

Arno Hueber1*, Sigrid Roters1, Jens F Jordan2 and Walter Konen1

Author Affiliations

1 Department of Ophthalmology, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany

2 University Eye Hospital Freiburg, 79106 Freiburg, Germany

For all author emails, please log on.

BMC Ophthalmology 2013, 13:35  doi:10.1186/1471-2415-13-35

Published: 18 July 2013



To evaluate the success rate and adverse effects of Gold Micro Shunt Plus (GMS+) implantation into the supraciliary space.


This retrospective study included 31 eyes of 31 patients diagnosed with severe glaucoma and uncontrolled intraocular pressure (IOP) with implantation of a GMS+ by means of a full-thickness scleral flap. The main outcome measures were surgical failure or success, based on the intraocular pressure and adverse effects. Clinical examination data are reported up to 4 years postoperatively.


Thirty eyes (97%) met one of our criteria for failure. Within a mean of 7.3 ± 7.7 months another surgery was performed because of elevated IOP in 24 of 31 eyes (77%) and because of adverse effects in 2 (6%). The remaining 4 eyes, that met one of our criteria for failure, had an IOP reduction of less than 20% with comparable medication. Six GMS+’s were explanted; because of IOP elevation, 2; rubeosis iridis, 2; and low grade inflammation, 2.


GMS+ implantation is not an effective method to control IOP in patients with glaucoma, when using our surgical technique. The reason for the found signs of chronic low grade inflammation or rubeosis iridis in 4 eyes (13%) remains unknown and has to be further investigated.

Glaucoma; Glaucoma drainage implants; Gold micro shunt; Shunt implantation to the supraciliary space